US approves Johnson & Johnson’s single-dose COVID-19 vaccine for emergency use

Johnson & Johnson's COVID-19 vaccine
Johnson & Johnson's COVID-19 vaccine is the third vaccine approved by the US government
  • J&J’s vaccine was found to be 66% effective at preventing moderate-to-severe COVID-19
  • J&J’s vaccine is single-dose and can be shipped and stored at normal refrigerator temperature.

Johnson & Johnson’s single-dose COVID-19 vaccine is now the third vaccine approved by the US government for people aged 18 and above. The other two vaccines that are being administered to Americans are Pfizer/BioNTech’s and Moderna’s two-dose vaccines. 

“We feel that each of these vaccines will be effective, will prevent hospitalization, deaths and should be used,” the acting commissioner of US FDA, Dr. Janet Woodcock said. Also Read: COVID-19 vaccine: Private hospitals in India subject to ceiling of Rs 250 per person per dose

In its global trial including 44,000 people, J&J’s vaccine was found to be 66% effective at preventing moderate-to-severe COVID-19 four weeks after inoculation. It was 100% effective in preventing hospitalization and death due to the virus.

There were very few serious side effects reported in the trial, which also offered preliminary evidence that the vaccine reduced asymptomatic infections. The vaccine is likely to gain popularity across the globe as it is single-dose and can be shipped and stored at normal refrigerator temperature. Also Read: Pfizer-BioNTech COVID-19 vaccine 85% effective after single shot, no longer needs ultra-cold storage

The J&J vaccine is also under review by the European Union, where deliveries are expected to start in April, reported Reuters.

J&J said on Friday that the company was developing a second-generation vaccine that would target the concerning South African variant, and it will be ready to start Phase I trials by this summer.

J&J’s vaccine uses a common cold virus known as adenovirus type 26 to introduce coronavirus proteins into cells in the body and trigger an immune response. J&J is testing a two-dose version of its vaccine, with results expected this summer, the report added. Also Read: When can we assume to have coronavirus under control? Not, until there’re fewer than 100 COVID-related deaths a day!

LEAVE A REPLY

Please enter your comment!
Please enter your name here